Latest News & Features
Biotechnology
Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere. 18 October 2022
Big Pharma
The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of. 13 October 2022
Big Pharma
Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue. 13 October 2022
Europe
European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU. 11 October 2022
Big Pharma
The partnership aims to progress drug discovery and development | Tech platform accelerates trials and provides higher quality trial data. 11 October 2022
Americas
Dispute against LabCorp claims wilful infringement | Plaintiff has also sued Illumina, Roche and Myriad in separate cases. 6 October 2022
Americas
HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue. 6 October 2022
article
Antiviral treatment could potentially be distributed across 117 countries | MPP looks for interest from potential sublicensees 4 October 2022
article
Bristows has announced that competition law expert Stephen Smith will be the new joint managing partner of the firm 4 October 2022
Big Pharma
Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels. 4 October 2022